These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 33061349)

  • 1. Clinically Important Deterioration Among Patients with Chronic Obstructive Pulmonary Disease (COPD) Treated with Nebulized Glycopyrrolate: A Post Hoc Analysis of Pooled Data from Two Randomized, Double-Blind, Placebo-Controlled Studies.
    Kerwin EM; Murray L; Niu X; Dembek C
    Int J Chron Obstruct Pulmon Dis; 2020; 15():2309-2318. PubMed ID: 33061349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of glycopyrrolate/eFlow
    Kerwin E; Donohue JF; Goodin T; Tosiello R; Wheeler A; Ferguson GT
    Respir Med; 2017 Nov; 132():238-250. PubMed ID: 28838685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of a novel, nebulized glycopyrrolate for the treatment of COPD: effect of baseline disease severity and age; pooled analysis of GOLDEN 3 and GOLDEN 4.
    Ohar J; Tosiello R; Goodin T; Sanjar S
    Int J Chron Obstruct Pulmon Dis; 2019; 14():27-37. PubMed ID: 30587959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of background long-acting beta
    Kerwin EM; Tosiello R; Price B; Sanjar S; Goodin T
    Int J Chron Obstruct Pulmon Dis; 2018; 13():2917-2929. PubMed ID: 30275690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol.
    Singh D; D'Urzo AD; Chuecos F; Muñoz A; Garcia Gil E
    Respir Res; 2017 May; 18(1):106. PubMed ID: 28558833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety of glycopyrrolate/eFlow
    Ferguson GT; Goodin T; Tosiello R; Wheeler A; Kerwin E
    Respir Med; 2017 Nov; 132():251-260. PubMed ID: 28919143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effect of Baseline Rescue Medication Use on Efficacy and Safety of Nebulized Glycopyrrolate Treatment in Patients with COPD from the GOLDEN 3 and 4 Studies.
    Donohue JF; Ozol-Godfrey A; Goodin T; Sanjar S
    Int J Chron Obstruct Pulmon Dis; 2020; 15():745-754. PubMed ID: 32341641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Gender on Lung Function and Patient-Reported Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate.
    Ohar JA; Ozol-Godfrey A; Goodin T; Sanjar S
    Int J Chron Obstruct Pulmon Dis; 2020; 15():995-1004. PubMed ID: 32440111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of SGRQ-Defined Chronic Bronchitis at Baseline on Treatment Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate.
    Tashkin DP; Ozol-Godfrey A; Sharma S; Sanjar S
    Int J Chron Obstruct Pulmon Dis; 2021; 16():945-955. PubMed ID: 33880019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study.
    Greulich T; Kostikas K; Gaga M; Aalamian-Mattheis M; Lossi NS; Patalano F; Nunez X; Pagano VA; Fogel R; Vogelmeier CF; Clemens A
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1229-1237. PubMed ID: 29713156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study.
    Anzueto AR; Kostikas K; Mezzi K; Shen S; Larbig M; Patalano F; Fogel R; Banerji D; Wedzicha JA
    Respir Res; 2018 Jun; 19(1):121. PubMed ID: 29925383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studies.
    Martinez FJ; Lipworth BJ; Rabe KF; Collier DJ; Ferguson GT; Sethi S; Feldman GJ; O'Brien G; Jenkins M; Reisner C
    Respir Res; 2020 May; 21(1):128. PubMed ID: 32450869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of glycopyrrolate in patients with COPD by reversibility: pooled analysis of GEM1 and GEM2 12-week studies.
    Ohar JA; Bowling A; Goodin T; Price B; Ozol-Godfrey A; Sharma S; Sanjar S
    Int J Chron Obstruct Pulmon Dis; 2019; 14():461-470. PubMed ID: 30863047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose selection for glycopyrrolate/eFlow
    Donohue JF; Goodin T; Tosiello R; Wheeler A
    Respir Res; 2017 Dec; 18(1):202. PubMed ID: 29202767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of twice-daily indacaterol/glycopyrrolate inhalation powder for the treatment of moderate to severe COPD in the US.
    Rajagopalan K; Bloudek L; Marvel J; Dembek C; Kavati A
    Int J Chron Obstruct Pulmon Dis; 2018; 13():3867-3877. PubMed ID: 30568438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA.
    Singh D; Fabbri LM; Vezzoli S; Petruzzelli S; Papi A
    Int J Chron Obstruct Pulmon Dis; 2019; 14():531-546. PubMed ID: 30880943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health-Related Quality of Life Improvements in Moderate to Very Severe Chronic Obstructive Pulmonary Disease Patients on Nebulized Glycopyrrolate: Evidence from the GOLDEN Studies.
    Ferguson GT; Kerwin EM; Donohue JF; Ganapathy V; Tosiello RL; Bollu VK; Rajagopalan K
    Chronic Obstr Pulm Dis; 2018 Jun; 5(3):193-207. PubMed ID: 30584583
    [No Abstract]   [Full Text] [Related]  

  • 18. The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD.
    Anzueto AR; Vogelmeier CF; Kostikas K; Mezzi K; Fucile S; Bader G; Shen S; Banerji D; Fogel R
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1325-1337. PubMed ID: 28496316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
    Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
    Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies.
    Martinez FJ; Rabe KF; Lipworth BJ; Arora S; Jenkins M; Martin UJ; Reisner C
    Int J Chron Obstruct Pulmon Dis; 2020; 15():99-106. PubMed ID: 32021148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.